Latest Lead News

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Terra Metals has secured an option to acquire a large tenement package adjacent to its flagship Dante Project, significantly expanding its exploration potential in Western Australia's West Musgrave region.

Strategic Energy Resources has completed a significant 25-hole drill program at its Achilles 1 Prospect, confirming widespread polymetallic mineralisation, while a new electromagnetic survey at its Mundi Project reveals promising conductors for further exploration.

CurveBeam AI Limited reported a remarkable 150% increase in device purchase orders in Q2 FY25, driven by strong demand for its HiRise™M platform and a new commercial agreement with Stryker. The company is advancing validation of its Enhanced HiRise™ for robotic surgical systems, despite a regulatory delay for its BMD SaaS module.

Litchfield Minerals has confirmed a substantial expansion of the Oonagalabi base metal system, extending its geochemical footprint beyond 3km. The company is gearing up for an aggressive 2025 exploration campaign, including geophysical surveys and drilling, despite potential weather-related delays.

AUCyber Limited has recommended shareholders accept an increased cash takeover offer from 5G Networks Limited, raising the bid by 22.7% to 13.5 cents per share amid ongoing financial uncertainties.

Atlas Arteria reports solid traffic and toll revenue growth in Q4 2024, led by strong light vehicle volumes and strategic toll increases across its global portfolio.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Whitehaven Coal delivered a robust Q2 FY25 with record sales volumes and production costs at the low end of guidance, while preparing for a major $1.08 billion capital inflow from its Blackwater mine stake sale.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.